期刊文献+

胰高血糖素样肽1受体表达及其生理功能的研究进展 被引量:7

原文传递
导出
摘要 糖尿病一般采用以生活方式干预为基础的口服药物和(或)胰岛素治疗。以胰高血糖素样肽1(GLP-1)为基础的新型降糖药物已在2型糖尿病患者的临床治疗中取得了良好的疗效3。GLP-1是一种主要由肠道L细胞产生的肠促胰岛素(incretin),通过特异性的GLP-1受体(GLP-1R)介导发挥生物学作用。GLP-1R属于G蛋白偶联受体B家族(分泌素家族)中的胰高血糖素受体亚家族,
出处 《中华糖尿病杂志》 CAS CSCD 2013年第3期183-186,共4页 CHINESE JOURNAL OF DIABETES MELLITUS
基金 国家自然科学基金项目(81070621/H0704、30971404/H0704) 江苏省自然科学基金(BK2007251) 江苏省国际科技合作计划一重点国别和地区研发合作项目(BZ2011042) 江苏省“兴卫工程”医学重点人才项目(RC2011068) 国家自然科学基金国际(地区)合作与交流项目NSFC-CIHR(中加)(81261120566)
  • 相关文献

参考文献34

  • 1Stephens JW. The incretin system in the management of type 2 diabetes mellitus. Clin Med,2010, 10:491-495.
  • 2Hoist J J, Gromada J. Role of inreretin hormone in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab ,2004,287 : E199-206.
  • 3Tornehave D, Kristensen P, Rcmer J, et al. Expression of the GLP-1 receptor in mouse, rat, and human pancreas. J Histochem Cytochem,2008,56 : 841-851.
  • 4Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology, 2007,132:2131-2157.
  • 5Orskov C, Poulsen SS. Glucagon like peptide-1-(7-36)-amide receptors only in islets of Langerhans. Diabetes, 1991,40: 1292- 1296.
  • 6Holz GG, Leech CA, Heller RS, et al. cAMP-dependent mobilization of intracellular Ca^2 + stores by activation of ryanodine receptors in pancreatic beta-cells. A Ca^2+ signaling system stimulated by the insulinotropic hormone glucagon-like peptide-1- (7-37). J Biol Chem, 1999,274 : 14147-14156.
  • 7Peffetti R, Merkel P. Glucagon-like peptide-1 : a major regulator of pancreatic beta-cell function. Eur J Endocrinol, 2000, 143 : 717- 775.
  • 8Drucker DJ. Glocagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology, 2003,144 : 5145 -5148.
  • 9Leech CA, Holz GC, Chepurny O, et al. Expression of cAMP- regulated guanine nucleotide exchange factors in pancreatic β- cells. Bioehem Biophys Res Commun,2000, 278:44-47.
  • 10Liu J, Yin F, Xiao H, et al. Glucagon-like peptide 1 receptor plays an essential role in geniposide attenuating lipotoxicity- induced β-cell apoptosis. Toxicol In Vitro, 2012,26 : 1093-1097.

同被引文献93

  • 1刘慧丽,袁立,杨云青.醛糖还原酶遗传缺失可显著减缓C57BL/6小鼠糖尿病肾病进程[J].中华糖尿病杂志,2010,2(5). 被引量:5
  • 2Ginter E, Simko V. Type 2 diabetes mellitus, pandemic in 21st century[J]. Adv Exp Med Biol, 2012,771:42-50.
  • 3Chiu TT, Jensen TE, Sylow L, et al. Racl signalling towards GLUT4/glucose uptake in skeletal muscle[J]. Cell Signal, 2011, 23: 1546-1554.
  • 4Pagotto U. Where Does Insulin Resistance Start?[J]. Diabetes Care,2009,32: 174-177.
  • 5Stuckli J, Fazakerley D J, James DE. GLUT4 exocytosis[J]. J Cell Sci,2011,124 Pt 24:4147-4159.
  • 6Niu W, Bilan PJ, Ishikura S, et al. Contraction-related stimuli regulate GLUT4 traffic in C2C12- GLUT4myc skeletal muscle cells[J]. Am J Pbysiol Endocrinol Metab, 2010, 298:E1058- 1071.
  • 7Ducommun S, Wang HY, Sakamoto K, et al. Thr649Ala-AS160 knock-in mutation does not impair contraction/AICAR-induced glucose transport in mouse muscle[J]. Am J Physiol Endocrinol Metab, 2012,302: E1036-1043.
  • 8Vilsbφll T 1, Zdravkovic M, Le-Thi T. Liraglutide, a long-acting human glucagon-like peptide-1 analog, siren as monotherapy significantly improves glycemie control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes[J]. Diabetes Care,2007,30:1608-1610.
  • 9Giannocco G, Oliveira KC, Crajoinas RO, et al. Dipeptidyl peptidase iv inhibition upregulates glut4 translocation and expression in heart and skeletal muscle of spontaneously hypertensive rats[J]. Eur J Pharmacol, 2013,698: 74-86.
  • 10Stockli J, Fazakerley D J, James DE. GLUT4 exoeytosis[J]. J Cell Sci,2011,124 Pt 24:4147-4159.

引证文献7

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部